Literature DB >> 7825223

Epidemiology, immunology and chemotherapy of Schistosoma mansoni infections in a recently exposed community in Senegal.

B Gryseels1, F F Stelma, I Talla, G J van Dam, K Polman, S Sow, M Diaw, R F Sturrock, E Doehring-Schwerdtfeger, R Kardorff.   

Abstract

Schistosoma mansoni was introduced in the Richard Toll area (Senegal) around 1988, probably due to man-made ecological changes in the Senegal river basin. Since 1991, we investigate the community of Ndombo, close to Richard Toll. Four random population samples of approximately 400 subjects are surveyed, starting at 8 months intervals. Each cohort is examined parasitologically (Kato-Katz), clinically, serologically (circulating antigen and antibody profiles); treated with praziquantel 40 mg/kg; and followed up 6-12 weeks, 1 and 2 years after treatment. Water contact patterns and snail densities are longitudinally surveyed. In the first cohort, prevalence of infection was 91%, with 41% excreting over 1000 eggs per gram (epg); the mean egg count was 646 epg, individual counts up to 24,000 epg. Prevalences remained almost 100%, but egg counts declined strongly in adults, in spite of continued exposure and the supposed lack of acquired immunity. Antigen detection in serum and urine confirmed that the egg counts genuinely reflect variations of worm burdens. Serum circulating anodic antigen (CAA) provided intriguing epidemiological information on worm burdens, while circulating cathodic antigen (CCA) showed promise for non-invasive diagnosis and screening. So far, similar epidemiological results were found in subsequent cohorts, although some variations were observed, possibly due to seasonal transmission fluctuations. IgE levels increased with age, while IgG4 peaked in the age-group 10-19 years. IgE and IgG4-levels against adult worm antigen (AWA) and soluble egg antigen (SEA) increased between cohort 1 and cohort 3 in almost all age-groups. In all 3 cohorts examined so far a strong correlation between IgG4 and pre-treatment egg-load was observed. Further follow-up and analysis, and comparison with chronically infected populations will provide insight in the development of acquired immunity. Abdominal discomfort was reported by 61% and diarrhoea by 33% of the subjects in the first cohort; mild hepatomegaly was found in 16%, splenomegaly in 0.5%. There was no correlation between frequency of symptoms and egg counts. This low morbidity, in spite of intense infections, was confirmed by ultrasound, and may be due to the recent nature of the focus. In the first cohort, 82% of treated subjects still excreted eggs 12 weeks after treatment, though egg counts declined strongly. Antigen detection confirmed these results. Parasitological negativation rates in subsequent cohorts, followed up sooner after treatment, improved but remained remarkably low. The low drug efficacy may be due to very rapid reinfection (though further reinfection after one year was limited), and/or to the lack of immunity in the population. Reduced susceptibility of the local schistosome strain can not be excluded, however. Praziquantel treatment provoked impressive but transient side effects (colics, vomiting, urticaria, oedema), the frequency of which correlated with intensity of infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7825223

Source DB:  PubMed          Journal:  Trop Geogr Med        ISSN: 0041-3232


  16 in total

Review 1.  Drug resistance in human helminths: current situation and lessons from livestock.

Authors:  S Geerts; B Gryseels
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  The contribution of water contact behavior to the high Schistosoma mansoni Infection rates observed in the Senegal River Basin.

Authors:  Seydou Sow; Sake J de Vlas; Foekje Stelma; Kim Vereecken; Bruno Gryseels; Katja Polman
Journal:  BMC Infect Dis       Date:  2011-07-18       Impact factor: 3.090

3.  Similar cellular responses after treatment with either praziquantel or oxamniquine in Schistosoma mansoni infection.

Authors:  Takafira Mduluza; Francisca Mutapi; Tinashe Ruwona; Daniel Kaluka; Nicholas Midzi; Patricia D Ndhlovu
Journal:  Malawi Med J       Date:  2009-12       Impact factor: 0.875

4.  Water level regulation and control of schistosomiasis transmission: a case study in Oyan Reservoir, Ogun State, Nigeria.

Authors:  I E Ofoezie; S O Asaolu
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

5.  Recent Advances in Schistosomiasis.

Authors:  G. Richard Olds; Srinivasan Dasarathy
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

Review 6.  New approaches for understanding mechanisms of drug resistance in schistosomes.

Authors:  Robert M Greenberg
Journal:  Parasitology       Date:  2013-04-03       Impact factor: 3.234

7.  Efficacy and side effects of praziquantel in the treatment of Schistosomiasis mansoni in schoolchildren in Shesha Kekele Elementary School, Wondo Genet, Southern Ethiopia.

Authors:  Berhanu Erko; Abraham Degarege; Konjit Tadesse; Asnake Mathiwos; Mengistu Legesse
Journal:  Asian Pac J Trop Biomed       Date:  2012-03

Review 8.  A research agenda for helminth diseases of humans: diagnostics for control and elimination programmes.

Authors:  James S McCarthy; Sara Lustigman; Guo-Jing Yang; Rashida M Barakat; Héctor H García; Banchob Sripa; Arve Lee Willingham; Roger K Prichard; María-Gloria Basáñez
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24

9.  Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni.

Authors:  Sandra D Melman; Michelle L Steinauer; Charles Cunningham; Laura S Kubatko; Ibrahim N Mwangi; Nirvana Barker Wynn; Martin W Mutuku; Diana M S Karanja; Daniel G Colley; Carla L Black; William Evan Secor; Gerald M Mkoji; Eric S Loker
Journal:  PLoS Negl Trop Dis       Date:  2009-08-18

10.  A Bayesian approach to estimate the age-specific prevalence of Schistosoma mansoni and implications for schistosomiasis control.

Authors:  Giovanna Raso; Penelope Vounatsou; Donald P McManus; Eliézer K N'Goran; Jürg Utzinger
Journal:  Int J Parasitol       Date:  2007-05-21       Impact factor: 3.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.